Proteina sintetizatzeko erabilitako aminoazidoen ezpurutasunak
Produktuaren xehetasuna
| NO | Aurrealdi | Cas ez | KALITATEAREN ADIERAZPENA | |||
| Garbitasun | Max. ezpain | Disolbatzaile guztizko hondakina | Umeltasun | |||
| 1 | FMOC-β-ALA-ALA-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 3 | FMOC-β-ALA-D-ALA-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 4 | Fmoc-arg (pbf) -arg (pbf) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 5 | FMOC-β-ALA-ARG (PBF) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 6 | FMOC-D-AR (PBF) -d-arg (pbf) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 9 | FMOC-β-ALA-HOMOARG (PBF) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 12 | FMOC-ASP (OTBU) -Zup (OTBU) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 13 | FMOC-β-ALA-ASP (OTBU) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 16 | Fmoc-cys (acm) -cys (acm) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 18 | FMOC-GLN (TRT) -gln (Trt) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 20 | Fmoc-glu (Otbu) -glu (Otbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 21 | Fmoc-β-ala-glu (Otbu) -oh.h2o | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 22 | Fmoc-β-ala-gly-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 23 | Fmoc-his (trt) -his (trt) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 24 | FMOC-β-ALA-HIE (TRT) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 25 | FMOC-ILE-ILE-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 26 | FMOC-β-ALA-ILE-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 30 | FMOC-β-ALA-D-Leu-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 31 | FMOC-LYS (BOC) -Lys (BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 32 | FMOC-β-ALA-LYS (BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 33 | Fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 34 | FMOC-β-ALA-LYS (Alloc) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 35 | FMOC-Bete-beteta-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 36 | FMOC-β-ALA-MET-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 37 | FMOC-Orn (BOC) -orn (bok) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 38 | FMOC-β-ALA-ORN (BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 39 | FMOC-PHE-PHE-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 40 | FMOC-β-ALA-PHE-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 41 | FMOC-D-Phe-D-Phe-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 42 | FMOC-β-ALA-D-PHE-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 43 | Fmoc-pro-pro-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 44 | FMOC-β-ALA-PRO-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 45 | Fmoc-ser (tbu) -Ser (tbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 46 | FMOC-β-ALA-SER (TBU) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 47 | Fmoc-ser (trt) -Ser (Trt) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 48 | FMOC-β-ALA-SER (TRT) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 49 | Fmoc-th (tbu) -th (tbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 50 | Fmoc-β-ala-th (tbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 51 | Fmoc-trp (boc) -trp (bok) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 53 | Fmoc-d-trp (boc) -d-trp (boc) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 56 | Fmoc-β-ala-tyr (tbu) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 60 | Fmoc-β-ala-tyr (me) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 61 | FMOC-Val-Val-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 62 | FMOC-β-ALA-VAL-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 63 | Fmoc-d-cit-d-cit-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 65 | FMOC-β-ALA-Dab-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 66 | Fmoc- (3- (2-naftil) -D-ALA) 2-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 67 | FMOC-β-ALA-3- (2-naftilia) -D-ala-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 68 | FMOC- (3- (3- Piridinyl) -D-ALA) 2-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 69 | FMOC-β-ALA-3- (3 piridinil) -D-ALA-OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 70 | FMOC- (4-kloro-D-PHE) 2-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 71 | FMOC-β-ALA-4-Chloro-D-Phe-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 72 | Fmoc- (D-4aph (TBUCBM)) 2-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 74 | Fmoc-aph (l-hor) -aph (l-hor) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 75 | FMOC-β-ALA-APH (L-Hor) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 76 | FMOC-LYS (IPR, BOC) -Lys (IPR, BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 77 | FMOC-β-ALA-LYS (IPR, BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 78 | Fmoc-β-ala-aeea-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 79 | FMOC-AIB-AIB-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 80 | FMOC-β-ALA-AIB-Oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 82 | H-AR (PBF) -oh | 200115-86-2 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 84 | HD-AR (PBF) -oh | 200116-81-0 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 86 | H-homoarg (pbf) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 88 | HD-homoarg (pbf) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 90 | H-asn (trt) -oh | 132388-58-0 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 92 | H-ASP (OTBU) -oh | 3057-74-7 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 94 | H-CYS (TRT) -OH | 2799/7/7 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 95 | H-CYS (ACM) -oh.hcl | 28798-28-9 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 97 | H-gln (trt) -oh | 102747-84-2 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 99 | H-glu (Otbu) -oh.h2o | 2419-56-9 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 100 | FMOC-HIE-OH | 116611-64-4 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 1011 | H-h her (trt) -oh | 35146-32-8 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 102 | Boc-bere-oh | 17791-52-5 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 104 | H-Lys (Boc) -oh | 2418-95-3 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 105 | H-Lys (Alloc) -OH | 6298/3/9 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 107 | H-orn (boc) -oh | 13650-49-2 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 108 | Fmoc-ser-oH | 73724-45-5 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 110 | H-ser (trt) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| Eta 112 | H-th (tbu) -oh | 4378-13-6 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 114 | H-trp (boc) -oh | 146645-63-8 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 116 | Hd-trp (boc) -oh | 201290-11-1 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 120 | HD-Tyr (et) -oh | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 121 | H-tyr (me) -oh.hcl | 67423-44-3 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 122 | FMOC-D-4aph (CBM) -oh | 324017-22-3 | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 123 | HD-4aph (TBUCBM) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 124 | FMOC-LYS (IPR) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
| 125 | H-Lys (IPR, BOC) -OH | NA | ≥98,0 | ≤1,0 | ≤8,0 | ≤2,0 |
Ei buruz
Kalte-ordain
Gentolex-ek kalitate handiko produktuak eskaintzen ditu, edozein produktu kalitatean bezeroak planteatzen badu behar den denbora-markoaren barruan, froga nahikoa izanez gero, beharrezko azterketa eta ebaluazioa eskainiko dugu kalte-orduen prozedurak eragiteko.
Ekoizpen
Produktu farmazeutikoen gaitasunak tonako kalifikazioa lortu zuten, produktu kimikoen gaitasunak 100 tsont + kalifikazioa lortzen dute, gaitasunak ondo hornituta daude mundu osoko bezeroei zerbitzatzeko.
Ikerketa eta garapena
Urtero, I + G taldeak produktu berri desberdinak garatzeko asmoa dago, helburuak ezarrita daudenean, taldeko kide guztiek KPI erantzukizunarekin eta pizgarri politikarekin jarraitu beharko dute.
